Results 121 to 130 of about 43,749 (262)

Developing a machine learning model to predict renal function decline within three years using one‐year longitudinal data in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
We developed a machine learning model to predict renal function decline in patients with type 2 diabetes and preserved kidney function. Using one year of routine clinical data, the model forecasts eGFR decline over three years, enabling early identification of high‐risk patients and supporting timely, targeted therapeutic interventions.
Mari Kaneda, Shu Meguro, Kaiken Kimura, Youichiro Harada, Makoto Enomoto, Kaori Hayashi   +5 more
wiley   +1 more source

Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art review. [PDF]

Heart Fail Rev
Van Spall HGC, Vardeny O.
europepmc   +1 more source

Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction To demonstrate noninferiority of continued sodium zirconium cyclosilicate therapy versus a potassium‐restricted diet in achieving normokalemia at Visit 7 (Days 28–42) in individuals with type 2 diabetes and hyperkalemia, using a noninferiority margin of −10 percentage points (one‐sided α = 0.025).
Masahide Hamaguchi, Junya Hironaka, Hiroshi Okada, Mari Yoneda, Ayaka Kobayashi, Yoshitaka Hashimoto, Aya Kitae, Noriyuki Kitagawa, Akio Kishi, Michiyo Ishii, Mai Asano, Masahiro Yamazaki, Toru Tanaka, Hanako Nakajima, Eiko Sato, Michiaki Fukui   +15 more
wiley   +1 more source

Mineralocorticoid receptor antagonists and mortality in hypertension: a systematic review and meta-analysis. [PDF]

J Hypertens
Teh JW, Comerford G, Surlis G, Curneen J, Krewer F, Smyth A, Lappin D, Mcevoy JW, Dennedy MC, Judge C.   +9 more
europepmc   +1 more source

Effects of age, sex, and renal function on bowel movement‐improving effects of Bifidobacterium bifidum G9‐1 on constipation in patients with type 2 diabetes mellitus and chronic kidney disease: A prespecified subgroup analysis of the BIRDIE study

Journal of Diabetes Investigation, EarlyView.
This prespecified subgroup analysis of the BIRDIE study demonstrated that Bifidobacterium bifidum G9‐1 improved stool consistency, bowel movement, and quality of life in patients with type 2 diabetes mellitus, chronic kidney disease, and specifically in age ≥ 65 years, male, and those with eGFR ≥60 mL/min/1.73 m2.
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Hiroaki Satoh, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +8 more
wiley   +1 more source

Brain Proteomic Responses to Glucocorticoids and Their Relationship With Transcriptome: A Systematic Meta-Analysis. [PDF]

FASEB J
Juszczak GR.
europepmc   +1 more source

The Mineralocorticoid Receptor and the Heart

Endocrinology, 2021
Celso E Gomez-Sanchez, Elise P Gomez-Sanchez   +1 more
openaire   +2 more sources

Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy

Journal of Diabetes Investigation, EarlyView.
Older age, atrial fibrillation, loop diuretic use, and higher eGFR variability predicted early eGFR dip. Continued SGLT2 inhibitor therapy preserved long‐term kidney function, although closer monitoring is warranted in patients receiving loop diuretics. ABSTRACT Aim To assess the prevalence, risk factors, estimated glomerular filtration rate trajectory,
Jangwook Lee, Dayoung Kang, Kyoung‐Ah Kim, Han Seok Choi, Soomin Jo, Joeun Kim, Jae Yoon Park, Seung Eun Lee   +7 more
wiley   +1 more source

Primary adrenal insufficiency in patients with bilateral adrenal metastases treated with curative ablative radiation therapy: A comprehensive review of literature and expert agreements for radiation practice. [PDF]

Clin Transl Radiat Oncol
Bennassi A, Debbi K, Giraud N, Belaïdi L, Durigova A, Salati E, Frikha S, Bellefkih FZ, Ksouri W, Hayel NE, Tsoutsou P, Geara F, Tesanovic D, Chammah SE, Ozsahin M, Droumaguet C, Belkacemi Y.   +16 more
europepmc   +1 more source

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Naoya Osaka, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Takanori Matsui, Sho‐ichi Yamagishi   +9 more
wiley   +1 more source